LivaNova reports Q1 adjusted EPS 98c, consensus 90c

Reports Q1 revenue $362.3M, consensus $346.11M. “In the first quarter, LivaNova (LIVN) delivered double-digit revenue growth with strength across all regions, driven by sustained performance in our Cardiopulmonary and Epilepsy businesses,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “We also made meaningful progress in Obstructive Sleep Apnea, accomplishing key regulatory and clinical milestones. These achievements support a solid foundation for entry into the high-growth, high-margin OSA market with a differentiated technology. Our updated 2026 guidance reflects strong execution in the core businesses alongside continued investment to unlock this next phase of growth and value creation. We remain focused on disciplined execution as we advance our long-term strategy, consistent with what we outlined at our November 2025 Investor Day.”